Improvement of Quality of Life by Cannabinoids in Oncologic Patients (BEfindLichkeitsverbesserung Unter CANnabinoid-ExtrakTen Bei Onkologischen Patienten)

The goal is to explore whether the application of cannabis extract Avextra 10/10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. The primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the Edmonton Symptom Assessment System total symptom distress score (ESAS TSDS) at baseline and after 12±2 days.

Start Date08 Apr 2024

Sponsor / Collaborator

Universitätsklinikum Schleswig-Holstein

[+1]

RBR-33f4vgr / RecruitingPhase 3IIT

Evaluation of the effectiveness of the use of Cannabinoids in controlling Neuropathic Pain in Low Back Pain

Start Date17 Jan 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cannabinoids

100 Translational Medicine associated with Cannabinoids

100 Patents (Medical) associated with Cannabinoids

7,107

Literatures (Medical) associated with Cannabinoids

01 Apr 2025·Neural Regeneration Research

Astrocytes, reactive astrogliosis, and glial scar formation in traumatic brain injury

Article

Author: Ramos, Alberto Javier ; Cieri, María Belén

Traumatic brain injury is a global health crisis, causing significant death and disability worldwide. Neuroinflammation that follows traumatic brain injury has serious consequences for neuronal survival and cognitive impairments, with astrocytes involved in this response. Following traumatic brain injury, astrocytes rapidly become reactive, and astrogliosis propagates from the injury core to distant brain regions. Homeostatic astroglial proteins are downregulated near the traumatic brain injury core, while pro-inflammatory astroglial genes are overexpressed. This altered gene expression is considered a pathological remodeling of astrocytes that produces serious consequences for neuronal survival and cognitive recovery. In addition, glial scar formed by reactive astrocytes is initially necessary to limit immune cell infiltration, but in the long term impedes axonal reconnection and functional recovery. Current therapeutic strategies for traumatic brain injury are focused on preventing acute complications. Statins, cannabinoids, progesterone, beta-blockers, and cerebrolysin demonstrate neuroprotective benefits but most of them have not been studied in the context of astrocytes. In this review, we discuss the cell signaling pathways activated in reactive astrocytes following traumatic brain injury and we discuss some of the potential new strategies aimed to modulate astroglial responses in traumatic brain injury, especially using cell-targeted strategies with miRNAs or lncRNA, viral vectors, and repurposed drugs.

01 Feb 2025·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review

Review

Author: Cammà, Guido ; van der Meer, Pim B ; van der Meer, Pim B. ; Verdouw, Monika P. ; Groenink, Lucianne ; Verdouw, Monika P ; Batalla, Albert

Interest in cannabinoids' therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids' therapeutic potential in psychiatric disorders. 22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8-THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9-THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.

01 Jan 2025·JOURNAL OF ETHNOPHARMACOLOGY

Cannabidiol finds dihydrocannabidiol as its twin in anti-inflammatory activities and the mechanism

Article

Author: Shi, Qiandai ; Xia, Yongmei ; Guo, Maoyue ; Wu, Qi ; Wang, Qiqi ; Zhu, Song

ETHNOPHARMACOLOGICAL RELEVANCE:

The hemp (cataloged at the "Medicinal Plant Names Services" as Cannabis sativa L.) extracts, cannabinoids have been used for centuries in Southeast Asia as folk medicines and now authorized by about 50 countries for application in medicine, health care products and cosmetics. As the most consumed cannabinoid, cannabidiol (CBD) has been recognized due to its various bioactivities, including anti-inflammatory and antibacterial properties.

AIMS OF THE STUDY:

The utilization of CBD is limited due to its potential conversion to psychoactive Δ9-tetrahydrocannabinol in strong acidic environment, demanding to excavate safer alternatives with clarified bioactivities. Yet the anti-inflammatory and antibacterial properties of CBD still remain unknown, in both of the performances and the corresponding mechanisms. Previously, a synthetic CBD analogue, H2CBD (Dihydrocannabidiol) was found to be effective as CBD does towards some antioxidantive activities and mouse seizure mitigation. Therefore, it is wondering if H2CBD also acted similarly as CBD does in the aspect of anti-inflammatory performance and mechanism, and the safety.

MATERIAL AND METHODS:

The anti-inflammatory properties of CBD and H2CBD were revealed with enzymatic assays, proteins denaturation and lipopolysaccharide (LPS) stimulated RAW264.7 cells model, with epigallocatechin gallate (EGCG) as the positive control. Their anti-inflammatory mechanism was revealed with ELISA and Western blot assay. The antibacterial properties of CBD and H2CBD were also investigated towards E. faecalis and B. cereus along with their synergistic effect with commercial antibiotics.

RESULTS:

CBD and H2CBD exhibited almost same (P > 0.05) performance in all the assayed anti-inflammatory properties, yet their anti-inflammatory efficiencies positively correlated to their antioxidantive activity. Moreover, both of CBD and H2CBD presented anti-inflammation to LPS stimulated RAW264.7 cells through NF-κB and AKT pathway. Furthermore, CBD and H2CBD also supplied strong and very similar (P > 0.05) antibacterial activities, comparable to tetracycline in same dose and strength. The erythrocyte hemolytic assay indicates CBD and H2CBD possessing the same safety. All the combinations of H2CBD with other cannabinoids or antibiotics present no antagonism against the bacteria, but nice synergistic or additive effect in some cases.

CONCLUSION:

CBD and H2CBD presented very similarly in all the assayed anti-inflammatory performances, undergoing same inflammatory mechanism with NF-κB and AKT pathway; they also expressed similar antibacterial activity, like twins. These findings will supply CBD a sustainable, safer and economic alternative with same excellent performances.

368

News (Medical) associated with Cannabinoids

14 Nov 2024

·www.globenewswire.com

Avicanna Reports Q3 2024

9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce results Q3 2024. “We are pleased to report the results of another quarter showing progressive improvements across our four business pillars. Our continuous optimization efforts contributed to improvements in our overall financial performance, consolidated gross margins, and balance sheet. We are now better positioned to turn our attention towards our international growth initiatives and take further steps towards advancing our long-term business model.” stated Aras Azadian, CEO at Avicanna Inc. Financial highlights: Revenue of $6.3 million and $18.8 million for the three- and nine-month period ending September 30, 2024, representing a 0.34% and 75% increase over the three- and nine-month period ended September 30, 2023, respectively.Improved consolidated gross margin percentage to 57% during Q3 2024, from 46% for the same period in 2023.Growth in gross profit of $3.7 million and $9.5 million, respectively, for the three- and nine month period ended September 30, 2024, compared to $2.9 million and $4.9 million for the same periods in 2023, an increase of 25% and 91%, respectively.Narrowed adjusted EBITDA loss for the three- and nine-month period ended September 30, 2024, narrowed to $293,931 and $719,347, respectively, a 38% and 76% decrease from an adjusted EBITDA loss of $473,650 and $3 million, respectively, in the corresponding periods last year.Fully repaid outstanding principle balance of approximately $1,300,000 owed under non-convertible debenture. Other highlights: The United States Patent and Trademark Office granted the Company a Patent, Patent No. US 20230025693A1, covering deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.The Company completed Q3 2024 with 35 commercial SKUs and 136 commercial listings. The Company sold approximately 45,126 and 144,756 units, for the three- and nine-month period ended September 30, 2024, respectively, compared to 31,887 and 118,265 compared to the same periods in 2023. This represents an increase of 42% and 22% growth in total finished goods sold, respectively. About Avicanna: Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based drug candidates aim to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients (“API”) supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing a various forms high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. The business unit also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 1, 2024, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a1191556-7e71-4d8d-b5d7-4bc0f5db4d6a

Financial Statement

12 Nov 2024

·www.globenewswire.com

Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44

HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected from a competitive field of numerous companies as one of the few U.S. bioscience cannabis companies invited to participate in the DEA hearings on the rescheduling of marijuana. Represented by CEO, Mr. Dante Picazo, CBIH will present clinical trial data showcasing the therapeutic benefits and potential of Cannabis sativa L., emphasizing the company’s commitment to pioneering innovative treatments. In its presentation, CBIH will provide robust evidence on the safety and efficacy of cannabis compounds in medical science, while highlighting the economic opportunities a rescheduling could unlock for the entire industry. “This opportunity reaffirms the importance of advancing cannabinoid research and development. The event provides a vital forum where regulatory authorities can engage directly with entrepreneurs, executives, physicians, scientists, patients, and other key industry stakeholders. Such interaction paves the way for a more informed and equitable regulatory framework for the sector,” says Mr. John Jones, Treasurer and Director of CBIH. From a financial standpoint, Charles Tamburello, Director of CBIH, underscores the importance of these conferences in solidifying the legitimacy of the medical cannabis market, a key factor in boosting investor confidence. According to a report by global market research firm Grand View Research, published in January 2024, the U.S. cannabis market was valued at $33.6 billion in 2023 and is projected to grow at a compound annual rate of 12.1% from 2024 to 2030. In the September 9, 2024, issue of Forbes, President-elect Donald Trump emphasized that rescheduling marijuana would pave the way for supportive legislation. He stated, "As president, we will prioritize research to unlock the medical potential of marijuana as a Schedule III drug and collaborate with Congress to pass practical laws, including safe banking options for state-authorized businesses and upholding states' rights to establish their own marijuana regulations." "We are deeply honored to participate in this landmark event, where CBIH will present groundbreaking data on cannabinoids’ potential to treat severe conditions such as cancer, epilepsy, neurodegenerative diseases, and osteoarthritis," expressed Rosangel Andrades, Director of Research and Development at CBIH. This participation underscores CBIH's commitment to continue developing safe, effective treatments and highlights the urgent need to advance research into cannabis’s therapeutic benefits. With ten patents submitted, CBIH is positioning itself as a leader in advocating for equitable regulation that would grant millions access to innovative solutions for improved quality of life. Participation in the DEA hearings marks a significant step toward a future where cannabinoid-based medicine becomes accessible to all. FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com. For more information contact us at:(214) 733-0868ir@cbih.netDante PicazoCEO - CBIHWebsite: www.cbih.netX: www.twitter.com/cbihstockInstagram: www.instagram.com/CBIHSTOCK

12 Nov 2024

·www.globenewswire.com

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures and rare disorders, today announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. The publication, entitled, “Neuroprotective effects of psilocybin in a rat model of stroke,” is published in BMC Neuroscience and is available here. The research and intellectual property were part of the acquisition of assets from PharmaTher Holdings Ltd (CSE: PHRM) (OTCQB: PHRRF) in February 2021. The research study supported the Company’s PCT application (PCT/CA2021/050360), titled, “Use of Psilocybin in the Treatment of Neurological Brain Injury and Migraines.” The objective of the research study was to determine the protective effect of psilocybin in cellular and animal models of stroke. In the study, psilocybin reduced brain infarction and improved locomotor behavior in stroke rats; the protective mechanisms involve regulating BDNF expression. Michael Frank, CEO of Revive, commented: “We have a diverse psilocybin-based pharmaceutical program that has been quietly moving forward with the aim of treating neurological, mental health and substance abuse disorders. The publication of the research study demonstrating psilocybin’s therapeutic potential in the treatment of stroke, which is often associated with subsequent depression, validates our strategic initiative to focus on evaluating psilocybin in clinical studies and novel delivery methods, such as our in-development psilocybin oral thin-film and microneedle patch.” About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com. For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank@revivethera.comWebsite: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the year ended June 30, 2024 ("MD&A"), dated October 25, 2024, which is available on the Company's profile at www.sedarplus.ca.

Orphan DrugFast Track

100 Deals associated with Cannabinoids

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 1	US	Cannabis Bioscience International Holdings, Inc.	20 Mar 2024
Alzheimer Disease	IND Approval	IT	Avextra Pharma GmbH	08 Oct 2024
Amyotrophic Lateral Sclerosis	IND Approval	IT	Avextra Pharma GmbH	08 Oct 2024
Parkinson Disease	IND Approval	IT	Avextra Pharma GmbH	08 Oct 2024
Brain Cancer	Preclinical	AU	Zelira Therapeutics Ltd.	24 Sep 2024
Brain Cancer	Preclinical	AU	Telethon Kids Institute	24 Sep 2024
Pancreatic Cancer	Preclinical	AU	Curtin University	24 Sep 2024
Pancreatic Cancer	Preclinical	AU	Zelira Therapeutics Ltd.	24 Sep 2024
Pelvic Inflammatory Disease	Preclinical	GB	Viramal Ltd.	23 Sep 2024
Breast Cancer	Preclinical	CA	Andira Medicine, Inc.Startup	25 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CRD42023479375 (ESMO2024)	Not Applicable	Cancer Pain	-	Cannabinoids	owhyofubjb(krjrwusisn) = qiwgoqlknm uiuwlngeky (lkiwvygtlk, -0.65 to 0.75) View more	Positive	15 Sep 2024
EAN	Not Applicable	Asphyxia Neonatorum	-	URB447 + TH	ndurkzwjbt(lzidexpyoh) = rvvfuzlfns xgscgaljlp (wumlykipbd ) View more	-	28 Jun 2024
				TH + URB447	ndurkzwjbt(lzidexpyoh) = ujbfpctshj xgscgaljlp (wumlykipbd ) View more
NCT03782402 (CTgov)	Phase 2	Peripheral Nervous System Diseases	12	Cannabinoids (Placebo Cannabinoids)	wdbkrzwtyo(jlvpbetfou) = wqxovbdjoa cmfdeuozzf (bncqppjozk, wyyhelcnap - upsgdlbqep) View more	-	26 Jan 2023
				Cannabinoids (Cannabinoids (THC and CBD))	xwmiyzolpu(labfvkernp) = gtkehjbhmn zgkjvxbzsg (mpinuejuaz, okumbwoknp - evlunshrdf) View more
EULAR2022	Not Applicable	Arthritis, Psoriatic	-	Cannabinoid	ugfgjhkhmh(xcvgcloaer) = 17.5% of patients with RA using cannabinoids reported side effects not leading to cessation jfovuluhmh (hprzsfmlvf )	-	01 Jun 2022
ISC2022	Not Applicable	Ischemic stroke	256	Cannabinoid positive	qoqiativmz(oaqgitjfud) = fahgaesejh fbifbskjqq (ykdwgcszgv )	-	01 Feb 2022
				Cannabinoid negative	qoqiativmz(oaqgitjfud) = llammdlrxg fbifbskjqq (ykdwgcszgv )
ASN2020	Not Applicable	Kidney Tubular Necrosis, Acute	-	Synthetic cannabinoids (SC)	ezlgxdskis(cxxgwulvkm) = A renal biopsy showed acute tubular injury with tubular dilatation, cytoplasmic simplification and vacuolization (image) ilohxfudpx (qtwpwrphnl ) View more	-	19 Oct 2020
SNMMI2020	Not Applicable	-	-	Regular users of legal marijuana	ylprcoueyc(ipkxyjldxk) = qayruxxjbo vvndjpzjgm (vnjizunlep )	-	15 May 2020
EAN	Not Applicable	Cluster Headache \| Migraine Disorders	-	THC+CBD 200 mg/day	rshjdprzrs(ictagvrjlq) = byjajkkcon yeakkbgznw (fztxgjmzkf ) View more	Positive	13 Jul 2017
				Amitriptyline 25mg/day	xxjsqajtxi(zrqbautccw) = qjkuxoxtnw mamqkijvul (pmqzqihzcf ) View more
Pubmed \| Drug Test Anal	Not Applicable	-	-	Cannabinol (CBN)	mtnxeiavhq(yjvsyloree) = xjogxwclgi glkvxfbmvb (bjyggsvidy )	-	01 Jun 2015
				11-nor-9-carboxy-THC (THCCOOH)	ixodsetvbh(bwvjcfesiw) = zsyomofzqx ajplbrwzvf (dmhaanhcxn )
ISRCTN62942668 (CUPID, Pubmed \| Health Technol Assess)	Phase 3	Brain Diseases \| Multiple Sclerosis	498	Δ(9)-tetrahydrocannabinol (Δ(9)-THC)	fjzqiqrmuh(lcysdrdsxv): hazard ratio = 0.92 (95% CI, 0.68 - 1.23)	-	01 Feb 2015
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cannabinoids

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation